Skip to main content
Clinical Trials/NCT06574945
NCT06574945
Completed
Phase 4

Efficacy and Safety of Propofol in Combination With Different Esketamine Doses for Anesthesia During Loop Electrosurgical Excision Procedure

Qian Wu1 site in 1 country90 target enrollmentJanuary 7, 2022

Overview

Phase
Phase 4
Intervention
intravenous injection of propofol +esketamine
Conditions
Esketamine
Sponsor
Qian Wu
Enrollment
90
Locations
1
Primary Endpoint
Respiratory Rate
Status
Completed
Last Updated
last year

Overview

Brief Summary

The goal of this prospective, randomized controlled study study is to investigate the efficacy and safety of propofol combined with different doses of esketamine (ESK) for anesthesia during loop electrosurgical excision procedure (LEEP).Ninety female patients undergoing LEEP were randomly allocated to three groups.It aims to answer :1.The effect of esketamine combined with propofol in respiration, circulation, etc,during LEEP. 2.The appropriate dosage of esketamine when combined with propofol in LEEP anesthesia.

Detailed Description

To investigate the efficacy and safety of propofol combined with different doses of esketamine (ESK) for anesthesia during loop electrosurgical excision procedure (LEEP). Ninety female patients undergoing LEEP were randomly allocated to three groups: group P (2 mg/kg propofol + saline), group propofol + esketamine(PK)1 (1.5 mg/kg propofol + 0.5 mg/kg ESK), and group PK2 (1.5 mg/kg propofol + 0.25 mg/kg ESK). Parameters including mean arterial pressure (MAP), heart rate (HR), respiratory rate (RR), oxygen saturation (SPO2), and venous carbon dioxide (PvCO2) were recorded. Additionally, the need for supplemental propofol, jaw thrust maneuver or ventilation, postoperative awakening time, and adverse reactions were assessed.

Registry
clinicaltrials.gov
Start Date
January 7, 2022
End Date
October 28, 2022
Last Updated
last year
Study Type
Interventional
Study Design
Parallel
Sex
Female

Investigators

Sponsor
Qian Wu
Responsible Party
Sponsor Investigator
Principal Investigator

Qian Wu

Principal Investigator

First Affiliated Hospital of Chongqing Medical University

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Patients who refused to participate
  • History of hypertension, hyperthyroidism, or neurological or mental disorder
  • Currently taking or has taken opioids and non-steroidal anti-inflammatory drugs within 48 h before surgery
  • Participated in other drug clinical trials within 4 weeks
  • Allergy to esketamine or propofol
  • History of opioid or esketamine addiction

Arms & Interventions

group PK1

Intravenous injection of 0.5 mg/kg esketamine followed by 1.5 mg/kg of propofol

Intervention: intravenous injection of propofol +esketamine

group P

Intravenous injection of an equivalent dose of normal saline followed by 2 mg/kg of propofol

Intervention: intravenous injection of propofol only

group PK2

Intravenous injection of 0.25 mg/kg esketamine followed by 1.5 mg/kg of propofol

Intervention: intravenous injection of propofol +esketamine

Outcomes

Primary Outcomes

Respiratory Rate

Time Frame: Immediately upon entering the operating room , 1 and 5 minutes after injection of anesthetics

The respiratory rate (RR) was monitored from 3-lead ECG

Heart Rate

Time Frame: Immediately upon entering the operating room , 1 and 5 minutes after injection of anesthetics

The heart rate (HR) was monitored using 3-lead ECG

Mean Arterial Pressure

Time Frame: Immediately upon entering the operating room, 1 and 5 minutes after injection of anesthetics

The mean arterial pressure (MAP) was monitored using Noninvasive blood pressure monitor

Venous Carbon Dioxide

Time Frame: Immediately upon entering the operating room and 5 minutes after injection of anesthetics

The venous carbon dioxide (PvCO2) was monitored using blood-gas analyzer

Secondary Outcomes

  • number of jaw thrust maneuver or face mask ventilation(On the day of surgery, from the instant the anesthesia induction is completed to the instant completion of surgery,up to 10 minutes)
  • incidences of postoperative vertigo, nausea, agitation and delirium(On the day of surgery,from the moment the patient wakes up (when MOAA score >4) to the moment the patient leaving the recovery room,up to 30minutes)
  • number of additional propofol usage(On the day of surgery, from the instant the anesthesia induction is completed to the instant completion of surgery,up to 10 minutes)
  • postoperative awakening time(On the day of surgery, from the instant completion of surgery to the moment the patient wakes up (when MOAA score >4),up to 10 minutes)

Study Sites (1)

Loading locations...

Similar Trials